NASDAQ:NVLN - Novelion Therapeutics Stock Price, News & Analysis

$0.87
+0.07 (+8.75 %)
(As of 09/17/2019 05:00 AM ET)
Today's Range
$0.78
Now: $0.87
$0.88
50-Day Range
$0.63
MA: $0.68
$0.8528
52-Week Range
$0.60
Now: $0.87
$4.04
Volume25,100 shs
Average Volume187,782 shs
Market Capitalization$16.57 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Novelion Therapeutics Inc, a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVLN
CUSIPN/A
Phone617-500-7867

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130.43 million
Book Value($4.69) per share

Profitability

Net Income$-108,330,000.00

Miscellaneous

Employees109
Market Cap$16.57 million
Next Earnings Date9/17/2019 (Estimated)
OptionableOptionable

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.


Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) announced its earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to the consensus estimate of $40.90 million. View Novelion Therapeutics' Earnings History.

When is Novelion Therapeutics' next earnings date?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, September 17th 2019. View Earnings Estimates for Novelion Therapeutics.

What is the consensus analysts' recommendation for Novelion Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novelion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novelion Therapeutics.

Has Novelion Therapeutics been receiving favorable news coverage?

Headlines about NVLN stock have been trending somewhat positive on Tuesday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novelion Therapeutics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Novelion Therapeutics.

Are investors shorting Novelion Therapeutics?

Novelion Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totalling 100,300 shares, a decrease of 28.6% from the July 31st total of 140,400 shares. Based on an average daily volume of 57,800 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.7% of the shares of the company are sold short. View Novelion Therapeutics' Current Options Chain.

Who are some of Novelion Therapeutics' key competitors?

What other stocks do shareholders of Novelion Therapeutics own?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:
  • Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Michael D. Price, Exec. VP & CFO (Age 61)
  • Mr. Roger W. Louis, Global Chief Compliance Officer and Head of R&D (Age 63)
  • Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)
  • Ms. Amanda Murphy, Director of Investor Relations & Corp. Communications

Who are Novelion Therapeutics' major shareholders?

Novelion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include EdgePoint Investment Group Inc. (14.87%), Highbridge Capital Management LLC (4.82%) and Stonepine Capital Management LLC (2.58%). View Institutional Ownership Trends for Novelion Therapeutics.

Which major investors are selling Novelion Therapeutics stock?

NVLN stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC. View Insider Buying and Selling for Novelion Therapeutics.

Which major investors are buying Novelion Therapeutics stock?

NVLN stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and EdgePoint Investment Group Inc.. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $0.87.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $16.57 million and generates $130.43 million in revenue each year. Novelion Therapeutics employs 109 workers across the globe.View Additional Information About Novelion Therapeutics.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is http://www.novelion.com/.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NASDAQ NVLN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel